Mar 28,2018

Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel

Nemaura Medical Inc., a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that it has appointed The Ruth Group (TRG), a leading healthcare-focused strategic communications firm, to lead its investor and public relations initiatives in the United States and help build awareness of the Company’s sugarBEAT® non-invasive continuous glucose monitoring (CGM) platform.

View Analyst & Ambassador Comments
Go to original news
Apr 03,2018

Benefits network Solera Health is launching a new platform called MedicareDPP.org

Benefits network Solera Health is launching a new platform called MedicareDPP.org, which will work as a referral and selection website for the Medicare Diabetes Prevention Program (MDPP). The platform, which is free to Medicare users, is designed to help educate users about diabetes risks and help them find local diabetes prevention programs. It was developed to guide users through their eligibility verification, blood value collection, and finding an MDPP provider.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 11,2018

Livongo signs deal with insurer Cambia Health Solutions

Digital chronic disease management company Livongo announced a partnership with nonprofit health insurance company Cambia Health Solutions. Cambia has six health plans in four states in the Pacific Northwest, covering 2 million members. The group is known for innovative thinking and strategic investing. Livongo will work with Cambia to roll out its existing diabetes management and hypertension management offerings to Cambia members, and to work with Cambia to create coaching and monitoring platforms for additional chronic conditions.

COLLABORATION PARTNERSHIP

#insurance

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 11,2018

Livongo gets $105 million funding in Series E

Digital chronic disease management company Livongo has raised $105 million in new Series E funding, mostly from existing investors. General Catalyst and Swedish investment company Kinnevik led the round, with additional participation from existing investors DFJ, Kleiner Perkins Caufield & Byers , Merck Global Health Innovation Fund, Microsoft Ventures, Sapphire Ventures, Zaffre Investments, and 7wire Ventures. The company also announced a partnership with nonprofit health insurance company Cambia Health Solutions.

FUNDING SERIES E
View Analyst & Ambassador Comments
Go to original news
Apr 17,2018

Livongo acquires weight-management company Retrofit

Digital chronic disease management company Livongo today announced that it has acquired Retrofit, a company that specializes in weight-management and disease prevention programs.

COLLABORATION MERGERS & ACQUISITION
View Analyst & Ambassador Comments
Go to original news
Apr 18,2018

Novo Nordisk, Sempre Health Partner for Better Patient Adherence

Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform. The partnership is hoping to engage 10,000 diabetes patients on Sempre’s platform within 2018. Sempre works with pharmacy benefit managers to inform patients about discounts on their prescriptions through text messages — and then those discounts change to incentivize healthy behaviors. Along with rewards for consistently refilling, Sempre works with payers and manufacturers and uses an algorithm to craft discounts that incentivize patients without extra cost to payers.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Apr 23,2018

UCSD launching pilot trial of glucose-sensing ‘tattoo’

Researchers from the University of California San Diego have developed a low-cost, single-use tattoo-like wearable that measures the user’s glucose levels. According to a release from the institution, this noninvasive technology will be at the center of a newly announced pilot clinical trial designed to test the accuracy and acceptability of the tattoos.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 01,2018

Intent-to-treat analysis of a simultaneous multisite telehealth diabetes prevention program

The study determines the effectiveness of a 16-week modified diabetes prevention program (DPP) administered simultaneously to multiple rural communities from a single urban site, as compared with a similar face-to-face intervention. A 12-week intervention was evaluated to consider minimization of staff costs in communities where resources are limited.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Apr 03,2018

ASCENSIA ANNOUNCES FINALISTS FOR THE ASCENSIA DIABETES CHALLENGE WHO HAVE THE POTENTIAL TO REVOLUTIONIZE TYPE 2 DIABETES MANAGEMENT

Today, Ascensia Diabetes Care has revealed the six entries that will progress to the finalist stage of the Ascensia Diabetes Challenge, a global innovation competition that is seeking digital solutions to support type 2 diabetes management. The six finalists were selected from 116 submissions that were received and were chosen by a panel consisting of external experts and members of the Ascensia Medical, R&D and Commercial teams. The selected companies will now present their solutions at the finalist event in April to determine the winner, which will subsequently be announced at the American Diabetes Association 78th Scientific Sessions in June.

View Analyst & Ambassador Comments
Go to original news
Apr 04,2018

Virta Health Raises $45 Million to Expand Treatment for Type 2 Diabetes Reversal

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) and other chronic metabolic diseases without the use of medications or surgery, announced it has raised a $45 million Series B funding round, bringing the total equity funding to $75 million to date. Key existing investors including Venrock, Obvious Ventures, Creandum, Caffeinated Capital, and Max Levchin’s SciFi VC participated in the round, along with new investors including Founders Fund and Playground Global.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES